BioSpace News Archive

Axogen, Inc. announced the independent publication of a comprehensive, retrospective clinical review comparing the meaningful recovery rates between allograft, autograft, and conduits using a meta-analysis methodology.

Genprex, Inc. announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors.

Esperovax, an innovative developer of oral mRNA biologics, and Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced a partnership to develop circular RNAs for a variety of therapeutic applications.

Shanghai Xianbo Biotech Co., Ltd. and BiTE-armed CAR-T cell therapies, and Orna Therapeutics today announced a collaboration agreement to discover, develop, and commercialize multiple potential therapeutics in the area of oncology.

B dot Medical Inc. has signed a memorandum of understanding with Edogawa Hospital in Japan for the installation of the company’s first practical ultra-compact proton therapy system, which means the first proton therapy facility to be established in Tokyo.

Sosei Group Corporation, the world leader in G protein-coupled receptor focused structure-based drug design and development, notes its partner Tempero Bio has announced FDA clearance of its Investigational New Drug application for TMP-301 for the treatment of alcohol and substance use disorders.

HighTide Therapeutics Inc., a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital.

ProLung, Inc. dba IONIQ Sciences, Inc. announced it is presenting in person at Biotech Showcase™, the investor conference for innovators.

Asensus Surgical, Inc. announced that the management team will participate and present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 PM PST.

Synlogic, Inc., a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, summarized accomplishments for 2022 and outlined anticipated key milestones for 2023.